• Citer

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study

par Ustianowski, Andrew;Levin, Myron;De Wit, Stéphane ;Launay, Odile;Veekmans, Bernard;Rampling, Tommy;Sullivan, James J.A.;Vishnepolsky, Mark;Wijewardane, Priyantha;Fawadleh, Yousef;Zhang, Huixia;Li, Meng;Wickramarachchi, Dilki;Sharbaugh, A.;Beavon, Rohini;Thissen, Jesse;Hirao, Lauren;Dzutseva, Vitalina;Seegobin, Seth;Streicher, Katie;Kiazand, Alexandre;Esser, Mark M.T.;Chang, Lee Jah;Perez, John J.L.;Cohen, Taylor Sitarik
Référence Clinical drug investigation, 46, 2, page (207-219)
Publication Publié, 2026-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study
Auteur:	Ustianowski, Andrew; Levin, Myron; De Wit, Stéphane; Launay, Odile; Veekmans, Bernard; Rampling, Tommy; Sullivan, James J.A.; Vishnepolsky, Mark; Wijewardane, Priyantha; Fawadleh, Yousef; Zhang, Huixia; Li, Meng; Wickramarachchi, Dilki; Sharbaugh, A.; Beavon, Rohini; Thissen, Jesse; Hirao, Lauren; Dzutseva, Vitalina; Seegobin, Seth; Streicher, Katie; Kiazand, Alexandre; Esser, Mark M.T.; Chang, Lee Jah; Perez, John J.L.; Cohen, Taylor Sitarik
Informations sur la publication:	Clinical drug investigation, 46, 2, page (207-219)
Statut de publication:	Publié, 2026-02
Sujet CREF:	Pharmacologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1173-2563
	info:doi/10.1007/s40261-025-01515-x
	info:scp/105027806045
	info:pmid/41545648